We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Specific Phenotype Narrows Risk of Preeclampsia

By LabMedica International staff writers
Posted on 10 Sep 2019
Preeclampsia can lead to a baby being born early and can put the mother at risk of a seizure or stroke during delivery. More...
It can also lead to damage in the kidneys, liver, lungs, heart or eyes and can increase a patient's risk for cardiovascular disease in the future.

The general female population has a 5% chance of developing preeclampsia during pregnancy, but that chance increases to 20% for diabetic women. Haptoglobin (Hp), a protein with functional genetic polymorphisms, has antioxidant, anti-inflammatory and angiogenic effects. Among people with diabetes, Hp 2-2 phenotype is associated with cardio-renal disease.

Endocrinologists at the Medical University of South Carolina (Charleston, SC, USA) and their colleagues investigated whether Hp phenotype is associated with preeclampsia (PE) in type 1 diabetes (T1DM), and/or modulates lipoprotein-associated risks. Included in the multicenter prospective study were 47pregnant women with T1DM (normal albuminuria, normotensive at enrolment, studied at three visits (V1-V3), all preceding PE onset: 12.3±1.9, 21.8±1.5, and 31.5±1.6 weeks gestation (mean ± SD). The main outcome measures were Hp phenotype and lipoprotein profiles in 23 women with versus 24 without subsequent PE.

The scientists reported that Hp phenotype did not predict PE, but lipoprotein associations with subsequent PE were confined to Hp 2-2 women, in whom the following associations with PE were observed: increased LDL-cholesterol, LDL particle concentration, Apolipoprotein B (APOB), triacylglycerol/high density lipoprotein cholesterol ratio, and APOB:APOA1 ratio; decreased HDL-cholesterol, APOA1, large HDL particle concentration, and peripheral lipoprotein lipolysis. In women with one or two Hp-1 alleles, no such associations were observed.

Clare B. Kelly, PhD, an Endocrinologist and first author of the study, said, “By studying these patients, we have identified different markers that could help predict the complication before its onset. Currently, we're taking the more reactive approach when it comes to preeclampsia. But if we know a patient is diabetic and has the 2-2 phenotype, we can monitor her more closely throughout her pregnancy and treat it proactively.” The study was originally published online on June 20, 2019, in The Journal of Clinical Endocrinology & Metabolism.

Related Links:
Medical University of South Carolina


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Graphical Abstract (Emery, J. K., V. Nemidkanam, N. Colon, et al. Journal of Extracellular Vesicles (2026). https://doi.org/10.1002/jev2.70286)

Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori

Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.